CEO Ron Cohen (Acorda)
January 13, 2021 11:06 AM ESTUpdated January 14, 09:58 AM
Deals
Manufacturing

Acor­da of­floads man­u­fac­tur­ing op­er­a­tions to Catal­ent for $70M amid lat­est re­struc­tur­ing to keep the ship afloat

Conner Mitchell

Just over a year af­ter the Supreme Court quashed any hopes Acor­da had of pro­tect­ing its once-lu­cra­tive mul­ti­ple scle­ro­sis drug Ampyra from cheap­er knock­offs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times